Prostate-Specific Antigen
"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
| Descriptor ID |
D017430
|
| MeSH Number(s) |
D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.140.625
|
| Concept/Terms |
Prostate-Specific Antigen- Prostate-Specific Antigen
- gamma-Seminoprotein
- gamma Seminoprotein
- Prostate Specific Antigen
- hK3 Kallikrein
- Kallikrein, hK3
- Semenogelase
- Kallikrein hK3
- Seminin
|
Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".
Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".
This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in this website by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 1 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 3 | 5 | 8 |
| 2016 | 2 | 3 | 5 |
| 2017 | 21 | 26 | 47 |
| 2018 | 13 | 40 | 53 |
| 2019 | 6 | 8 | 14 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles.
-
Is there still a role for digital rectal examination in the prostate cancer diagnostic pathway in the COVID-19 and post COVID-19 era? Aging Male. 2021 Dec; 24(1):92-94.
-
Dealing with cancer screening in the COVID-19 era. Rev Assoc Med Bras (1992). 2021; 67Suppl 1(Suppl 1):86-90.
-
Prostate specific antigen in COVID-19 patients. Andrology. 2021 07; 9(4):1042.
-
Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. JAMA Oncol. 2021 03 01; 7(3):458-460.
-
Management of prostate cancer radiotherapy during the COVID-19 pandemic: A necessary paradigm change. Cancer Treat Res Commun. 2021; 27:100331.
-
68Ga-PSMA PET/CT With Incidental Finding of COVID-19 in an Asymptomatic Patient. Clin Nucl Med. 2020 Dec; 45(12):1032-1033.
-
Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas. Curr Radiopharm. 2020; 13(2):94-98.
-
Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators. Eur Urol Oncol. 2020 10; 3(5):700-704.
-
Minimally Invasive Radical Prostatectomy after Previous Bladder Outlet Surgery: A Systematic Review and Pooled Analysis of Comparative Studies. J Urol. 2019 09; 202(3):511-517.
-
Accuracy of the preoperative PSA level for predicting clinically significant incidental transitional zone-prostate cancer before endoscopic enucleation of very large adenoma. World J Urol. 2020 Apr; 38(4):993-1000.